Aug 10, 2026 6:30am EDT Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Aug 04, 2026 8:30am EDT Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
Jul 30, 2026 8:30am EDT Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
Jul 27, 2026 8:10am EDT Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Jul 07, 2026 8:30am EDT Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
May 13, 2026 6:30am EDT Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Mar 09, 2026 8:30am EDT Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Feb 19, 2026 8:30am EST Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
